MGTX - MeiraGTx Holdings plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
14.19
-0.18 (-1.22%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close14.36
Open14.35
Bid0.00 x 800
Ask0.00 x 800
Day's Range14.00 - 14.45
52 Week Range8.53 - 30.23
Volume179,832
Avg. Volume189,715
Market Cap518.918M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.62
Earnings DateAug 7, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est35.25
Trade prices are not sourced from all markets
  • Globenewswire Test

    MeiraGTx to Present at Upcoming Scientific and Investor Conferences

    LONDON and NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the Company will present at the following upcoming events: 3rd Annual Chardan Genetic Medicines Conference in New YorkAlexandria Forbes, Ph.D., president and chief executive officer, will participate in a fireside chat at the Chardan Genetic Medicines Conference on October 7, 2019 from 1:30 p.m. – 1:55 p.m. ET, and will participate on a panel titled “Emerging Disease Areas in Gene Therapy” on October 7, 2019 from 9:30 a.m. – 10:15 a.m. ET.A live webcast of the fireside chat can be accessed through the Investors page of the Company's website at https://investors.meiragtx.com. A replay of the webcast will be available on the Company's website for 30 days following the live presentation.Jefferies Gene Therapy/Editing Summit in New YorkDr. Forbes will participate on a panel at the Jefferies Gene Therapy/Editing Summit on October 8, 2019 from 10:20 a.m. – 11:10 a.m. ET titled “Manufacturing, Dose, and Durability in Gene Therapy”.American Academy of Ophthalmology (AAO) 2019 Annual Meeting in San Francisco Michel Michaelides, BSc MB BS MD(Res) FRCOphth FACS, trial investigator, Consultant Ophthalmologist, Moorfields Eye Hospital and Professor of Ophthalmology, University College London, will present data at the Retina Subspecialty Day of the AAO Annual Meeting on the Company’s Phase 1/2 open-label, multi-center, dose-finding trial evaluating AAV-RPE65 in patients with RPE65-associated retinal dystrophy on October 12, 2019 at 9:17 a.m. PT.Professor Michaelides will also present a poster titled “Development and Validation of a Vision-Guided Mobility Assessment for RPE65-Associated Retinal Dystrophy” in a poster discussion session on October 14, 2019 at 12:30 p.m. PT. The poster describes the validation of a novel mobility assessment that is sensitive to the visual impairment of individuals with RPE65-associated retinal dystrophy.In the Phase 1/2 trial of AAV-RPE65, subjects navigated this mobility test at timepoints before and after treatment in order to assess the impact of AAV-RPE65 on functional vision.Conference Call and Webcast Information MeiraGTx will host a conference call and live webcast following Professor Michaelides’ presentation at AAO to review the data from the Phase 1/2 trial on October 12, 2019 at 5:30 p.m. PT. The live webcast can be accessed by visiting the Investors page of the Company’s website at https://investors.meiragtx.com. Please connect at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call 1 (866) 796-1272 (U.S.) or 1 (409) 937-8924 (International) to listen to the live conference call. The conference ID number for the live call is 5291617. A replay of the webcast and accompanying presentation materials will be available on the Company’s website for 30 days following the live conference call.About MeiraGTx MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, neurodegenerative diseases and severe forms of xerostomia and xerophthalmia. Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases. For more information, please visit www.meiragtx.com.Contacts  Investors: MeiraGTx Elizabeth Broder (646) 860-7983 Investors@meiragtx.com  or Media: W2O pure Christiana Pascale (212) 257-6722 cpascale@purecommunications.com

  • GlobeNewswire

    MeiraGTx To Present Clinical Data from Phase 1/2 Trial of AAV-RPE65 at Upcoming Scientific Conferences

    MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced that clinical data updates from the Company’s Phase 1/2 trial of AAV-RPE65 will be presented at two upcoming medical meetings. The Phase 1/2 open-label, multi-center, dose-finding trial evaluated AAV-RPE65 in patients with retinal dystrophy associated with disease-causing variants in the RPE65 gene, a condition that causes severe sight impairment beginning at birth. AAV-RPE65 is a second-generation gene therapy candidate developed specifically to treat RPE65-deficiency, and optimized for transduction efficiency, potency and stability.

  • Could MeiraGTx Holdings plc's (NASDAQ:MGTX) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could MeiraGTx Holdings plc's (NASDAQ:MGTX) Investor Composition Influence The Stock Price?

    Every investor in MeiraGTx Holdings plc (NASDAQ:MGTX) should be aware of the most powerful shareholder groups...

  • GlobeNewswire

    MeiraGTx Announces Pricing of Public Offering of Ordinary Shares

    LONDON and NEW YORK, Aug. 08, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced the pricing of an underwritten public offering of 3,200,000 of its ordinary shares at a public offering price of $23.50 per share. In addition, MeiraGTx has granted the underwriters a 30-day option to purchase up to an additional 480,000 of its ordinary shares at the public offering price, less underwriting discounts and commissions. BofA Merrill Lynch, Piper Jaffray and Chardan are acting as joint book-running managers of the offering.

  • GlobeNewswire

    MeiraGTx Announces Proposed Public Offering of Ordinary Shares

    LONDON and NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has commenced an underwritten public offering of $75 million of its ordinary shares. In connection with the offering, MeiraGTx intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ordinary shares sold in the public offering. All of the ordinary shares are being offered by MeiraGTx.

  • GlobeNewswire

    MeiraGTx Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    LONDON and NEW YORK, Aug. 07, 2019 -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial.

  • Why McEwen Mining, MeiraGTx Holdings, and Electronic Arts Slumped Today
    Motley Fool

    Why McEwen Mining, MeiraGTx Holdings, and Electronic Arts Slumped Today

    Find out why these stocks had significant drops.

  • 3 Small-Cap Biotech Stocks That Soared Last Week
    Motley Fool

    3 Small-Cap Biotech Stocks That Soared Last Week

    It was a great week for these three stocks, but can they continue climbing?

  • Hedge Funds Have Never Been This Bullish On MeiraGTx Holdings plc (MGTX)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On MeiraGTx Holdings plc (MGTX)

    Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of March. At Insider Monkey, we follow nearly 750 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]

  • Estimating The Intrinsic Value Of MeiraGTx Holdings plc (NASDAQ:MGTX)
    Simply Wall St.

    Estimating The Intrinsic Value Of MeiraGTx Holdings plc (NASDAQ:MGTX)

    How far off is MeiraGTx Holdings plc (NASDAQ:MGTX) from its intrinsic value? Using the most recent financial data...

  • 3 Biotech Stocks That Soared Last Week: Are They Buys?
    Motley Fool

    3 Biotech Stocks That Soared Last Week: Are They Buys?

    Can these high-flying biotech stocks keep the momentum going?

  • Why This Biotech Stock Looks Prime For A Johnson & Johnson Buyout
    Investor's Business Daily

    Why This Biotech Stock Looks Prime For A Johnson & Johnson Buyout

    Dow Jones component Johnson & Johnson could buy out biotech stock MeiraGTx for its efforts in gene therapy, an analyst suggested Friday. MeiraGTx is working on treatments for eye diseases.

  • GlobeNewswire

    MeiraGTx Reports First Quarter 2019 Financial Results and Provides Corporate Update

    • Positive 6-month results from Phase 1/2 clinical trial of AAV-RPE65 • Enrollment completed in the Phase 1/2 clinical trial investigating AAV-CNGB3 gene therapy for the.

  • GlobeNewswire

    MeiraGTx Announces Positive 6-Month Data from Phase 1/2 Trial of Investigational Gene Therapy AAV-RPE65 for RPE65-Deficiency

    LONDON and NEW YORK, May 14, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced positive data from a Phase 1/2 dose escalation trial of AAV-RPE65, the Company’s investigational gene therapy for the treatment of RPE65-deficiency, a condition that causes blindness. AAV-RPE65 is a second-generation gene therapy candidate developed specifically to treat RPE65-deficiency, and optimized for transduction efficiency, potency and stability. The trial enrolled 15 patients, including nine young adults (aged 16-24 years old) across three dose escalation cohorts, and six children (aged 5-12 years old) in a pediatric expansion cohort.

  • GlobeNewswire

    MeiraGTx Appoints Nicole Seligman to Board of Directors

    LONDON and NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Nicole Seligman to its Board of Directors. Ms. Seligman is an accomplished leader with extensive executive, legal, compliance and governance experience. “We are delighted to welcome Nicole to the MeiraGTx Board of Directors at this exciting time for the company,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx.

  • GlobeNewswire

    MeiraGTx to Present at Bank of America Merrill Lynch Healthcare Conference

    LONDON and NEW YORK, May 06, 2019 -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes,.

  • GlobeNewswire

    MeiraGTx Announces Upcoming Presentation on Achromatopsia Gene Therapy Candidate AAV-CNGA3 at ARVO 2019

    LONDON and NEW YORK, April 25, 2019 -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced a pre-clinical poster.

  • The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences
    Zacks

    The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences

    The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences

  • 5 Biotech Stocks Defying the Medicare-for-All Scare
    Zacks

    5 Biotech Stocks Defying the Medicare-for-All Scare

    Unlike the broader healthcare sector, biotech stocks have notched up strong gains year to date.

  • GlobeNewswire

    MeiraGTx Reports Full Year 2018 Financial Results

    LONDON and NEW YORK, March 26, 2019 -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial.

  • 10 Stocks For The Gene Therapy Revolution
    Investopedia

    10 Stocks For The Gene Therapy Revolution

    Gene therapy, which treats genetic diseases by replacing faulty genes, is a rapidly growing field, with merger activity on the rise.

  • GlobeNewswire

    MeiraGTx to Present at the Barclays Global Healthcare Conference

    LONDON and NEW YORK, March 06, 2019 -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that.

  • Why NOW Is the Time to Buy Gene Therapy Stocks
    InvestorPlace

    Why NOW Is the Time to Buy Gene Therapy Stocks

    The biotech industry has been on a tear in 2019, up 25% through the first two months of the year. That's great. But niche gene therapy stocks are performing even better.Source: Shutterstock The rally has been fueled by a strong combination of merger announcements, positive news from the FDA and the continued development of breakthrough therapies. Headlines have been popping up nonstop over the last week, and today I'd like to recap some of the highlights. Spark Therapeutics (NASDAQ:ONCE), a small-cap biotech that focuses on gene therapies, was purchased by pharmaceutical giant Roche (OTCMKTS:RHHBY). On a per-share basis, the $4.8 billion purchase price equated to $114.50 -- a huge 122% premium over ONCE's previous close. Spark investors are now looking at 190% gains in 2019 alone.The same day, CRISPR Therapeutics (NASDAQ:CRSP) announced that human trials had begun for its CTX001 gene therapy drug. A patient suffering from beta-thalassemia had been dosed. And in just a few months, the same drug is expected to be tested on patients with sickle cell disease.InvestorPlace - Stock Market News, Stock Advice & Trading TipsCTX001, which is based on the CRISPR/Cas9 gene editing technique, is currently undergoing Phase I/II trials. Typically, the first dose in such a trial would not be a headline. But this was the first time that CRISPR technology had ever been used on a human. The news sent CRSP up more than 20%. * 7 Top-Rated Stocks to Buy for March A few days later, gene therapy stock Sarepta Therapeutics (NASDAQ:SRPT) released impressive results for its muscular dystrophy drug. And in the same press release it announced the $165 million purchase of privately-held gene therapy company Myonexus. The stock rallied on the news and is now up 34% so far this year. But even with the acquisition news, SRPT has long been rumored as a takeover target for larger pharmaceutical companies.Finally, micro-cap gene therapy stock MeiraGTx Holdings (NASDAQ:MGTX) announced an $80 million private placement. This is important because its lead investor is the private arm of Johnson & Johnson (NYSE:JNJ). MeiraGTx is already up a whopping 67% in 2019. Get in Position for Life-Changing Profits from Gene Therapy StocksThere is absolutely no question that there is money to be made in the gene therapy stocks over the long term. However, because the sector is still in its infancy, we have to expect increased volatility. What we're seeing now is a very strong upswing.Gene therapy is on track to save countless lives. It's also on track to make you life-changing profits as long as you can weather the ups and downs that are simply the nature of early-stage mega-trends.Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Retail Stocks Ready to Break Out * 7 Strong Buy Stocks the Street Loves * 10 Best Stocks to Buy and Hold Forever Compare Brokers The post Why NOW Is the Time to Buy Gene Therapy Stocks appeared first on InvestorPlace.